Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03033108 |
Recruitment Status :
Completed
First Posted : January 26, 2017
Results First Posted : April 27, 2021
Last Update Posted : May 19, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stargardt Disease Macular Atrophy | Drug: Emixustat | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease |
Actual Study Start Date : | January 2017 |
Actual Primary Completion Date : | November 2017 |
Actual Study Completion Date : | December 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Emixustat Dose 1
lowest dose of once-daily oral emixustat
|
Drug: Emixustat
Once daily, tablet for oral administration
Other Name: emixustat hydrochloride |
Experimental: Emixustat Dose 2
middle dose of once-daily oral emixustat
|
Drug: Emixustat
Once daily, tablet for oral administration
Other Name: emixustat hydrochloride |
Experimental: Emixustat Dose 3
highest dose of once-daily oral emixustat
|
Drug: Emixustat
Once daily, tablet for oral administration
Other Name: emixustat hydrochloride |
- Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram [ Time Frame: Baseline and 1 month ]Percent suppression compared to baseline of rod b-wave amplitude recovery after a photobleaching light.
- Percentage of Subjects With Adverse Events, by Severity and Seriousness [ Time Frame: 1 month ]Assessment of safety profile

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria, including, but not limited to:
- Clinical diagnosis of macular atrophy (MA) secondary to Stargardt disease (STGD) in one or both eyes
- At least 2 pathogenic mutations of the ABCA4 gene
- Early Treatment Diabetic Retinopathy Study BCVA of ≥ 20 letters (approximately ≥ 20/400 Snellen) in the study eye
- Adequate clarity of ocular media and adequate pupillary dilation to permit good quality imaging of MA in the study eye
- Able and willing to provide written informed consent before undergoing any study-related procedures
- Able to reliably administer oral medication by self or with available assistance
Exclusion Criteria, including, but not limited to:
- Macular atrophy associated with a condition other than STGD in either eye.
- Presence in either eye of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function.
- History of any intraocular or ocular surface surgery in either eye within 3 months of screening.
- Current or previous participation in an interventional study to treat STGD using gene therapy or stem cell therapy at any time, or participation in an interventional study of a vitamin A derivative ≤3 months prior to screening.
- Pre-specified laboratory abnormalities at screening
- Presence of other medical or ophthalmic disease, physical examination finding, or clinical laboratory finding that in the opinion of the Investigator may contraindicate the use of an investigational drug and place the subject at risk
- Current or history of cancer (except for adequately treated basal cell or squamous cell carcinoma of the skin) within 1 year of screening
- History of myocardial infarction, stroke, unstable ischemic heart disease, uncontrolled cardiac arrhythmia, or hospitalization for congestive heart failure within 6 months of screening.
- Anticipated hospitalization for a medical/surgical procedure(s) that could result in interruption/premature cessation of study treatment or participation.
- Electrocardiogram with a clinically significant abnormal finding
- Female subjects who are pregnant or lactating
- Female subjects of childbearing potential or male subjects who are not surgically sterile who are not willing to practice a medically accepted method of birth control with their sexual partner from screening through 30 days after the final dose of study drug

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03033108
United States, Texas | |
Dallas, Texas, United States, 75231 |
Study Director: | Acucela Medical Director, MD | Kubota Vision Inc. |
Documents provided by Kubota Vision Inc.:
Responsible Party: | Kubota Vision Inc. |
ClinicalTrials.gov Identifier: | NCT03033108 |
Other Study ID Numbers: |
4429-204 |
First Posted: | January 26, 2017 Key Record Dates |
Results First Posted: | April 27, 2021 |
Last Update Posted: | May 19, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Stargardt Disease Macular Degeneration Anetoderma Atrophy Pathological Conditions, Anatomical Eye Diseases, Hereditary Eye Diseases |
Retinal Degeneration Retinal Diseases Genetic Diseases, Inborn Connective Tissue Diseases Skin Abnormalities Skin Diseases |